1. Which Products and Manufacturers Fall within GLOBE?
The Global Benchmark for Efficient Drug Pricing model targets certain high-spend, single-source drugs and sole-source biological products under Original Medicare Part B. Coverage alone does not establish inclusion; product classification, spending criteria and exclusions also matter.
Product Exclusions Require a Separate Review
The final rule excludes biosimilars and their reference biological products once a biosimilar enters the U.S. .arket. Other exclusions cover orphan-only drugs, plasma-derived products and certain cell and gene therapies. Manufacturers should check the specific criteria rather than rely on a product’s commercial description.
Participation Waivers Depend on Applicable Terms
A product exclusion differs from a manufacturer participation waiver. CMS describes using GENEROUS model participation agreements to waive mandatory GLOBE participation where necessary to evaluate that model. The company’s Medicare regulatory review should document the relevant agreement terms and covered quarters; a voluntary pricing announcement alone does not establish either.
2. How International Reference Pricing Shapes Rebate Exposure
International reference pricing uses overseas prices to establish a domestic benchmark. GLOBE applies that approach through an alternative manufacturer rebate calculation, rather than a general ceiling on U.S. .ist prices.
Method I Uses Existing Pricing Information
Method I relies on existing commercial international pricing information to estimate the lowest price among reference countries, subject to specified economic adjustments. Exposure estimates should distinguish total Part B sales from applicable units furnished to beneficiaries in the model cohort.
Method II Uses Voluntary Manufacturer Data
Method II uses voluntarily submitted international net-price data to establish an average international price, also subject to economic adjustments. Legal, finance and overseas commercial teams should assess whether product presentations, sales and net prices can be reconciled consistently before deciding to submit.
Declining Submission Does Not Remove Model Exposure
A manufacturer’s decision against voluntary submission does not remove it from otherwise applicable GLOBE requirements. Submission also does not guarantee CMS acceptance or a particular financial outcome, so the company should document both its data assessment and financial assumptions.
3. What Phrma’S Lawsuit Challenges
PhRMA filed its challenge in the U.S. District Court for the District of Columbia on October 7, 2026. It argues that CMS exceeded its model-testing authority under Section 1115A of the Social Security Act. These arguments are allegations, not judicial findings.
Whether GLOBE Fits CMS’S Testing Authority
The complaint questions whether GLOBE qualifies as a permissible test and whether CMS has rewritten statutory rebate provisions rather than waived requirements. CMS maintains that its testing and waiver authority permits the alternative rebate approach.
Statutory and Constitutional Limits
PhRMA also invokes the major questions doctrine and raises constitutional objections involving the Presentment Clause and nondelegation doctrine. These arguments concern the limits of agency authority, beyond disagreement over pricing policy.
Requested Relief Is Different from an Issued Order
The complaint seeks rule cancellation, postponement of effectiveness and injunctive relief. For companies monitoring administrative litigation, a requested injunction, an issued preliminary order and a final judgment setting aside the rule must remain separate developments.
4. Which Dates Govern Preparation?
The final rule separates legal effectiveness, initial reporting and model performance. Companies should maintain distinct calendar entries for these milestones and revise them when a controlling court order or agency action changes an obligation.
November 30, 2026: Regulatory Effective Date
The regulation becomes effective on November 30, 2026 under the final rule’s schedule. That date does not mean the performance period or the first voluntary reporting window begins at the same time.
January 1–30, 2027: First Voluntary Reporting Window
The first voluntary reporting window covers international net-price data for October–December 2026 sales. Manufacturers considering Method II should assess data readiness before that window opens rather than wait until model performance begins.
April 1, 2027: Performance Period Begins
The performance period runs from April 1, 2027 through March 31, 2032. Relevant model rebate and beneficiary payment provisions apply during this period, subject to the rule’s conditions and subsequent legal developments.
Payment Activities Continue Beyond Performance
The scheduled payment period runs through March 31, 2034, with completion potentially extending beyond that date under the rule. This period accommodates calculation, invoicing and reconciliation; its endpoint is not an individual invoice deadline.
5. What Manufacturers Should Prepare While Litigation Continues
Readiness work should connect pharmaceutical regulatory compliance with pricing and finance. A useful review produces product-specific conclusions, assigned responsibilities and records that teams can update as the model develops.
Document Coverage and Financial Assumptions
Record potentially affected products, exclusion grounds, waiver terms and assumptions supporting rebate estimates. Assign responsibility for international pricing records, validation and submission decisions so unresolved questions have a clear owner.
Change the Calendar Only on a Verified Basis
Before revising a compliance deadline, identify the court order or agency action that changes it, the obligations covered and the relevant dates. The existence of litigation alone does not establish that a scheduled requirement has been suspended.
16 Oct, 2026
